# A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

> **NCT07680829** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Zhejiang Doer Biologics Co., Ltd.** · enrollment: 378 (estimated)

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** DR10624 Subcutaneous Injection
- **DRUG:** Icosapent Ethyl Oral Capsule
- **DRUG:** Matching Placebo Subcutaneous Injection

## Key facts

- **NCT ID:** NCT07680829
- **Lead sponsor:** Zhejiang Doer Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2030-06
- **Final completion:** 2030-10
- **Target enrollment:** 378 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680829, "A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07680829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*